No price history available.
Key financial summary
Financials in CLP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CLPm | 212,266 | 276,854 | 259,992 | 202,263 | 172,059 | 165,196 | N/A | N/A |
| Operating profit | CLPm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CLPm | -5,280 | 18,417 | 4,047 | -3,401 | -78,463 | -65,468 | N/A | N/A |
| EPS reported | CLP | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CLP | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CLP | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CLP | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CLPm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CLPm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CLPm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CLP | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CLP | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CLP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Clínica Las Condes S.A. operates hospital centers in Chile. It provides services in the areas of anesthesia and pain, adult bronchopulmonary, cardiology, adult surgery, cardiovascular and endovascular surgery, pediatric surgery, plastic and reconstructive surgery, dermatology, gastroenterology, gynecology and obstetrics, maxillofacial, physical medicine and rehabilitation, internal medicine, neurosurgery, neurology adults, child neurology, nutrition, dentistry, ophthalmology, otorhinolaryngology, pediatrics, adult psychiatry, child and adolescent psychiatry, traumatology, CLC urgency, urology. The company was founded in 1982 and is based in Las Condes, Chile. Clínica Las Condes S.A. is a subsidiary of Lucec Tres S.A.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Clínica Las Condes S.A. (LAS-CONDES.SN)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Clínica Las Condes S.A. operates hospital centers in Chile. It provides services in the areas of anesthesia and pain, adult bronchopulmonary, cardiology, adult surgery, cardiovascular and endovascular surgery, pediatric surgery, plastic and reconstructive surgery, dermatology, gastroenterology, gynecology and obstetrics, maxillofacial, physical medicine and rehabilitation, internal medicine, neurosurgery, neurology adults, child neurology, nutrition, dentistry, ophthalmology, otorhinolaryngology, pediatrics, adult psychiatry, child and adolescent psychiatry, traumatology, CLC urgency, urology. The company was founded in 1982 and is based in Las Condes, Chile. Clínica Las Condes S.A. is a subsidiary of Lucec Tres S.A.